CANCER HAS NO BORDERS NEITHER DO WE



Delivering Lifesaving Oncology Therapies to Canadians

A MESSAGE FROM PETER BRENDERS, GENERAL MANAGER, BEIGENE CANADA

"At BeiGene Canada, our vision is clear—to be the driving force behind the delivery of lifesaving oncology therapies to Canadians. With an unwavering commitment to innovation, compassion, accessibility, and affordability, we are determined to rewrite the narrative of cancer care."

Cancer has touched the lives of countless individuals, including my own family. It is a battle that demands our unwavering commitment to better care. At BeiGene Canada, we are not just another pharmaceutical company, we are a force of innovation, tirelessly fighting back against this relentless disease.

Our passion lies in revolutionizing the landscape of cancer treatment in Canada. We understand the urgent need for essential and affordable therapies, and we are dedicated to making a tangible difference in the lives of those affected. By embracing a unique approach, we focus on areas of great unmet need, ensuring that no patient is left behind.

The global cancer population knows no boundaries, and neither do we. Whether in Canada, the United States, China, Europe, or any corner

of the world, cancer does not discriminate based on location. It is a universal enemy, and we stand united in our mission to defeat it. By transcending borders, we maximize our impact, extending impactful medicines to those who need them most.

At BeiGene Canada, our vision is clear-to be the driving force behind the delivery of lifesaving oncology therapies to Canadians. With an unwavering commitment to innovation, compassion, accessibility, and affordability, we are determined to rewrite the narrative of cancer care.

Join us on this transformative journey as we empower patients, inspire hope, and redefine what is possible in the fight against cancer. Together, let's pave the way toward a future where all Canadians has access to the lifesaving treatments they deserve.



ABOUT BEIGENE

As a fast-growing biotechnology company, we specialize in cutting-edge therapeutics and pioneering clinical trials for the most challenging forms of cancer. At BeiGene our mission is to deliver impactful medicines to those who need them the most. We believe in a better way of bringing the highest quality therapies to patients worldwide and transforming lives through accessible medicine.

P



Faster, More Affordable Innovation

Innovation is at the heart of what we do. We continuously strive to develop medicines that push boundaries and set new standards of care. But we don't just focus on innovation alone. We are driven to make these transformative drugs more affordable and readily available. By streamlining processes and leveraging our global expertise, we aim to expedite the journey from development to patient access.

Global Reach, Local Impact With a unified sense of urgency, our passionate team of over 9,400 colleagues spans the globe, securing regulatory approvals in more than 60 markets across five continents. We are committed to challenging the status quo and breaking down barriers to ensure that our medicines reach more patients everywhere.

Cancer has no borders. Neither do we

Revolutionizing Cancer Treatment





Our Visionary Founders

BeiGene was co-founded in 2010 by John Oyler, an esteemed American entrepreneur, and Dr. Xiaodong Wang, a renowned member of the U.S. Academy of Science and Director of China's National Institute of Biological Sciences (NIBS) in Beijing. Fueled by courage and persistent innovation, they set out to disrupt the pharmaceutical industry, driven by their belief that cancer knows no borders.

Together, we seek to create a world where life-changing medicines are not just a possibility, but a reality for all.

BEIGENE IN CANADA

Unleashing Hope: Empowering **Canadians in the Fight Against Cancer**

BeiGene Canada is at the forefront of our global mission to revolutionize cancer treatment. With a strong commitment to improving patient outcomes and accessibility, we are dedicated to helping Canadians in their battle against cancer.

Based in Toronto, Ontario, and supported by a nationwide network of colleagues, BeiGene Canada is focused on bringing cutting-edge cancer therapies to the Canadian oncology community. Our goal is to ensure that patients, caregivers, clinicians, and investigators have timely access to innovative and affordable medications in the areas of blood cancers and solid tumors. By prioritizing the needs of Canadian patients, we are making a tangible difference in their lives.

We understand the challenges that accompany a cancer diagnosis, and that's why we bring together a global team of talented individuals who share our vision of patient-centered care. By collaborating

with leading academic institutions, biotech, and pharmaceutical companies, as well as patient advocacy groups, we are able to create a unified force to support our mission.

Our goal is to unleash hope and transform the landscape of cancer treatment in Canada. But we can't do it alone. Together we can translate our passion into purpose, providing Canadian patients with the guidance and support they need throughout their journey.

LEADERSHIP

Extending the Boundaries of What is Possible

BeiGene Canada is led by a highly experienced and dedicated Canadian team with a shared passion for extending the boundaries of what is possible. In collaboration with our global colleagues, we aim to deliver on our promise of bringing bestin-class. affordable and accessible treatments to the Canadian oncology community.



Peter Brenders General Manager



Sharon Safranyos Senior Director **Regulatory Affairs**



Andrea Schwarz



Commercial Lead Hematology



Jason Bonnyman Commercial Lead Solid Tumor



Nathalie Desrosiers Senior Director Value, Access & Policy Director



Brad Gillesby, Ph.D **Country Medical**





Blair Dugan Senior Director Human Resources



Ashley Riley Senior Director Compliance



Alex Koutrouvelis Senior Franchise Counsel



César Miguel Guzmán Finance

PRODUCTS

BeiGene is proud to bring impactful medicines to patients in Canada and beyond. Our focus lies in developing a high-value product portfolio, specifically targeting blood cancers and solid tumors, with the goal of discovering first-in-class or best-in-class innovative medicines.

Among our achievements is the approval of BRUKINSA[®] (zanubrutinib) in Canada for the following indications:

- Waldenström's Macroglobulinemia Approved in March 2021
- Relapsed Refractory Mantle Cell Lymphoma (MCL) – Approved in July 2021
- Relapsed or refractory Marginal Zone Lymphoma (MZL) – Approved in March 2022
- Chronic Lymphocytic Leukemia (CLL) Approved in May 2023

With our expertise in these heterogeneous hematological malignancies and their significant differences in clinical presentation, we are working to redefine the possibilities for therapeutic intervention and shaping the future of cancer treatment.





BRUKINSA® is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), discovered by BeiGene scientists. It is currently being evaluated worldwide in an extensive clinical program, both as a monotherapy and in combination with other therapies, to treat various B-cell malignancies. Our commitment to global impact is reflected in BRUKINSA®'s approval in over 65 markets, including the United States, China, the European Union, Great Britain, Australia, South Korea, Switzerland, and Canada.



Putting Patients First: Empowering Lives Through Innovative Medicine

PATIENTS

At BeiGene, our commitment is to prioritize patients above all else. Our singular goal is to create high-guality innovative medicines that transform lives. But we don't stop there. We strive to ensure these ground-breaking treatments are accessible to those who need them most. We actively engage with cancer communities in Canada and worldwide, listening and learning from patients, caregivers, and families. By understanding their unique challenges and needs, we provide vital support, raise awareness, and improve lives. Together, we are forging a path towards better outcomes and brighter futures.

myBeiGene

The myBeiGene® patient support program supports patients, caregivers, and healthcare providers with access to BRUKINSA®. It goes beyond financial support to provide disease education, information on treatment with BRUKINSA[®], as well as emotional support by making connections to third-party resources to address individual needs. Oncology Case Managers are available Monday through Friday from 8 a.m. to 8 p.m. Eastern Time at 1-833-234-4366.

() talk about it

BeiGene recognizes the importance of making mental health and emotional wellness an integral part of quality cancer care for patients and their caregivers. We are committed to elevating the conversation on cancer and mental health among patients, caregivers, healthcare professionals and policy and access decisions makers. BeiGene's Talk About It program helps raise awareness, encourage dialogue, and, most importantly, ensure that all those impacted by cancer have the best tools to support their journey to wellness.



As a research-based pharmaceutical company we are keenly aware of what it takes to transform a concept into an evidence-based therapeutic. In addition to investing in research and development on a global scale, we highly value local ingenuity. The BeiGene Canada Fund for Research and Innovation is fostering partnerships with cancer care stakeholders across the country to provide seed money for projects related to human health research, including biomedical research, clinical research, health systems and services, including health policy and population health. For additional information and to apply, please visit www.beigene.ca/en-ca/fund/.

Uniting Forces for Patient Impact

STRATEGIC PARTNERSHIPS

BeiGene is at the forefront of collaborative innovation, joining forces with top-tier minds in academia, biotech, and pharma. Together we strive to deliver the highest quality and most innovative therapies to billions of people worldwide. Our partnerships are rooted in a shared vision of patient-centricity and a dedication to transformative science.

Accelerating Development **Broadening Access**

We forge strategic alliances that not only accelerate the development of groundbreaking treatments but also expand market access to innovative medicines for patients battling lifethreatening diseases. By building sustainable capabilities, we drive the rapid advancement of therapies that can change lives.

At BeiGene Canada, we are proud to contribute to the health and well-being of Canadians. In addition to our research and innovation efforts, we actively support and collaborate with recognized organizations and associations within the healthcare industry. Collaboration is key in creating medicines that truly benefit the communities we serve.

We proudly work alongside the following esteemed groups:





LEUKEMIA & LYMPHOMA SOCIETY OF Canadian Organization for Rare Disorders



Affiliations and Collaborations **Strengthening the Canadian** Healthcare Landscape

Together, we can transform lives and shape a brighter future for patients around the world.





Unleashing Potential: Our People, Our Culture

OUR TEAM

"Our employees are at the heart of everything we do. We foster a culture that empowers them to reach their full potential, enabling us to bring innovative, affordable, and accessible treatments to Canadian patients and clinicians." - Peter Brenders, General Manager, BeiGene Canada





Achievement with Integrity

At BeiGene, we not only focus on what we accomplish but how we achieve it. Integrity, trust, respect, and unwavering commitment to compliance and ethics define our approach to business. Our local and global teams are known for delivering high-quality work that transforms science and improves patient outcomes.





A Certified Great Place to Work[™]

BeiGene Canada proudly holds the Great Place to Work[™] certification, placing us among the leading organizations in Canada that excel at creating exceptional workplaces. Our culture of excellence is driven by employee recognition, accommodation, and ample opportunities for personal and professional growth. We provide incentives that inspire our team to thrive and contribute their best.

Work. Certified NOV 2022 - OCT 2023 CANADA

Great Place

То

Together, we can unleash the potential within each of us to make a meaningful impact on the lives of Canadians.



Cancer has no borders. Neither do we.



💥 @BeiGeneGlobal

Linkedin.com/Company/BeiGene

647-496-7420